Trials / Completed
CompletedNCT02645981
Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma
Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma: a Controlled,Multicentre,Randomised, Phase 3 Trial
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 668 (actual)
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Donafenib versus sorafenib for advanced hepatocellular cancer.
Detailed description
This phase 3 study of donafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, is to assess efficacy and safety in patients wiht advanced hepatocellular carcinoma (HCC).The study is a randomised,controlled,multicentre study.The controlled drug is sorafenib(Nexavar).The primary endpoint is overall survival.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Donafenib | Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects |
| DRUG | Sorafenib | Control |
Timeline
- Start date
- 2016-03-01
- Primary completion
- 2019-11-27
- Completion
- 2019-12-17
- First posted
- 2016-01-05
- Last updated
- 2020-01-09
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02645981. Inclusion in this directory is not an endorsement.